ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1869

FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients

Andreas Wiggers Nielsen1, Ib Tønder Hansen2, Berit Dalsgaard Nielsen3, Søren Geill Kjær4, Jesper Blegvad-Nissen4, Christian Møller Sørensen3, Ellen-Margrethe Hauge1, Lars Christian Gormsen2 and Kresten Krarup Keller1, 1Aarhus University Hospital, Aarhus, Denmark, 2Aarhus University Hospital, Aarhus N, Denmark, 3Department of Internal Medicine, Horsens, Denmark, 4Diagnostic Centre, Silkeborg, Denmark

Meeting: ACR Convergence 2023

Keywords: Imaging, Inflammation, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1862–1894) Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Polymyalgia rheumatica (PMR) can be challenging to diagnose since other diseases may present with similar symptoms. As a result, a significant number of patients are referred to rheumatologists for a second opinion. However, a notable proportion of patients are administered prednisolone prior to rheumatologic assessment, which can obscure the symptoms of PMR and important differential diagnoses. 18F-fluorodeoxyglucose(FDG) positron emission tomography and computed tomography (PET/CT) has been suggested as a potential tool to aid the clinician diagnosing PMR, but it is unclear whether PET/CT can be used after the initiation of prednisolone. This study aimed to investigate the diagnostic utility of FDG-PET/CT in patients suspected of PMR, specifically evaluating the diagnostic accuracy before, during, and after a short-term taper of prednisolone.

Methods: This study included 101 patients who were suspected of having PMR. All patients were clinically diagnosed with PMR or non-PMRat a baseline visit and subsequently had a PET/CT performed. Patients diagnosed with PMR were administered prednisolone with a starting dose of 15 mg following the first PET/CT. After 8 weeks of treatment a second PET/CT was performed when prednisolone had been tapered to 10 mg, according to an algorithm reflecting routine care. Afterwards, prednisolone was tapered with complete cessation at week 9 followed by a third PET/CT at week 10. A PET/CT assessment of PMR or non-PMR was given utilizing the validated Leuven score (Figure 1) [1]. The final diagnosis for all patients was confirmed at a 1-year follow-up visit.

Results: Preliminary results of the first 79 patients have been obtained, and the baseline characteristics of the PMR and non-PMR group are outlined in table 1. A baseline PET/CT diagnosis showed a sensitivity of 88.7% and a specificity of 61.5% using a clinical diagnosis at 1 year as the reference standard (Figure 1). The low specificity was partially explained by a high rate of false positive patients with a final diagnosis of other inflammatory diseases, since 8 out of 10 non-PMR patients with a final diagnosis of rheumatoid arthritis or reactive diseases had a PET/CT indicating PMR according to the Leuven score. After 8 weeks of prednisolone treatment the Leuven score decreased significantly, but in 14/46 patients the PET/CT diagnosis remained positive for PMR (Figure 2). After prednisolone cessation the Leuven score increased significantly, with a positive PET/CT diagnosis of PMR in 25/37.

Conclusion: Initiation of prednisolone treatment prior to PET/CT significantly reduces the diagnostic accuracy for a PMR diagnosis. Therefore, a short-term prednisolone taper is advisable before using PET/CT to diagnose PMR in patients treated with a medium dosage of prednisolone. Furthermore, PET/CT utilizing the Leuven score may not be reliable for differentiating PMR from other inflammatory disorders during the initial evaluation.

References [1] Henckaerts L, Gheysens O, Vanderschueren S, Goffin K, Blockmans D. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica-A prospective study of 99 patients. Rheumatology (Oxford) 2018;57(11):1908-16.

Supporting image 1

Table 1 – Baseline data of patients with a final diagnosis of PMR and non-PMR (control group) based on 1-year follow-up visit

Supporting image 2

Figure 1 – PET/CT diagnosis of PMR at baseline, 8 weeks and 10 weeks using the Leuven score.

Supporting image 3

Figure 2 – Box plot of Leuven score at baseline, after 8 weeks of prednisolone treatment and at 10 weeks after a 2 week prednisolone taper.


Disclosures: A. Nielsen: None; I. Hansen: None; B. Dalsgaard Nielsen: None; S. Kjær: None; J. Blegvad-Nissen: None; C. Sørensen: None; E. Hauge: AbbVie/Abbott, 2, 5, 6, Danish Regions Medicine Grants, 5, Danish Rheumatism Association, 5, Galapagos, 5, Novartis, 2, 6, Novo Nordic, 2, 5, 6, Sanofi, 2, 6, Sobi, 2, 6; L. Gormsen: None; K. Keller: None.

To cite this abstract in AMA style:

Nielsen A, Hansen I, Dalsgaard Nielsen B, Kjær S, Blegvad-Nissen J, Sørensen C, Hauge E, Gormsen L, Keller K. FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/fdg-pet-ct-for-diagnosing-polymyalgia-rheumatica-before-during-and-after-a-short-term-prednisolone-cessation-a-prospective-study-of-101-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fdg-pet-ct-for-diagnosing-polymyalgia-rheumatica-before-during-and-after-a-short-term-prednisolone-cessation-a-prospective-study-of-101-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology